|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Trial** | **Description** | | **Eligibility** | **Coordinator/PI** |
| **COLORECTAL** | | | | |
| **METASTATIC (FIRST LINE)** | | | | |
| **NRG-GI-004-CIRB** | COMMIT Study: Randomized Phase 3 trial of mFOLFOX6/bev w/w/o atezolizumab or atezolizumab monotherapy in 1st line dMMR mCRC | | 1st line mCRC with MSI-H (dMMR) mCRC | Catherine Griffin/Sanoff |
| **A021703** | SOLARIS: Randomized trial of vitamin D supplementation in untreated metastatic CRC | | Dealer’s choice (FOLFOX vs FOLFIRI) + bevacizumab | Brian Burgess/Sanoff |
| **METASTATIC CRC (2nd or 3rd line)** | | | | |
| **LCCC 1717 *(1 slot open for the naïve cohort)*** | Phase II single-arm study of palbociclib and cetuximab in RAS/RAF wildtype metastatic CRC | | One cohort open: RAS wildtype, EGFRi naïve | Catherine Griffin/Sanoff |
| **RGX-202-001 *(Currently only open for CKB + patients -> amendment coming that gets rid of this requirement)*** | A phase I study of RGX-202-01, small molecular inhibitor of creatine transporter with FOLFIRI | | 2nd line CRC with FOLFIRI + Bev + RGX (Expansion phase: patients must be CKB + and received only one prior regimen considered SOC for colorectal cancer in the advanced/metastatic setting, and it must have been an oxaliplatin-containing regimen) | Brian Burgess/Sanoff |
| **ADJUVANT CRC** | | | | |
| **A021502** | Randomized trial of chemo vs chemo + atezo as adjuvant therapy for patients with Stage III colon cancer and dMMR | | MSI-H CRC; Can have received one cycle of FOLFOX prior to enrollment | Brian Burgess/Sanoff |
| **NRG-GI-005-CIRB** | A Phase II/II Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA) | | Resected stable stage IIA colon cancer for which physician decides no adjuvant chemotherapy ("suitable for active surveillance") | Catherine Griffin/Sanoff |
| **PANCREATIC CANCER** | | | | |
| **19-529** | | Phase II Trial of ERK Inhibition Alone and in Combination with Autophagy Inhibition in Patients with Metastatic Pancreatic Cancer | At least one prior line of therapy | Catherine Griffin/ Somasundaram |
| **LCCC1843** | | Impact of Neoadjuvant FOLFIRINOX on Tumor and Stromal Subtypes in Subjects with Non-Metastatic Pancreatic Cancer | Correlative study of patients receiving neoadjuvant FFX; can receive chemotherapy locally | Catherine Griffin/Somasundaram |
| **PACER (19-0556) - SUSPENDED** | | PACER (Pancreatic AdenoCarcinoma with Electron intraoperative Radiation therapy): A Phase II study of electron beam intraoperative radiation therapy following chemoradiation in patients with pancreatic cancer with vascular involvement | Patients must receive at least 3 months of neoadjuvant chemotherapy and SBRT or CRT prior to surgery | Kyle Wang (Not run in GI POD) |
| **BILIARY** | | | | |
|  | |  |  |  |
| **HEPATOCELLULAR CARCINOMA** | | | | |
|  |  | |  |  |
| **PHASE I GI TRIALS** | | | | |
| **849-001** | A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation | | Pancreatic and CRC with KRAS G12C mutations | Jared Weiss (Not run in GI POD) |
| **GASTROESOPHAGEAL** | | | | |
|  |  | |  |  |
| **ANAL SCC** | | | | |
|  |  | |  |  |
| **NEUROENDOCRINE TUMOR** | | | | |
| **A021602 – On Hold** | Randomized phase III study of cabozantinib vs placebo in patients with advanced NET after progression on everolimus | | Placebo controlled with crossover | Brian Burgess/Sanoff |

**Study Coordinator Contacts:**

Brian Burgess (Lead)

(p) 984-974-8772

(f) 919-962-2621

(e) [brian\_burgess@med.unc.edu](mailto:brian_burgess@med.unc.edu)

Catherine Griffin

(p) 984-974-8771

(f) 919-962-2621

(e) [catherine\_griffin@med.unc.edu](mailto:catherine_griffin@med.unc.edu)

Hayatu Abdullahi

(p) 919-445-4864

(f) 919-962-2621

(e) [habdul@email.unc.edu](mailto:habdul@email.unc.edu)